The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis

Biochemical Pharmacology

Volumn 65, Issue 5, 2003, Pages 765-771

  Hooijberg, Jan Hendrik ^a   Peters, Godefridus J ^a   Assaraf, Yehuda G ^b   Kathmann, Ietje ^a   Priest, David G ^c   Bunni, Marlene A ^c   Veerman, Anjo J P ^a   Scheffer, George L ^a   Kaspers, Gertjan J L ^a   Jansen, Gerrit ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Folate homeostasis; Folic acid; Leucovorin; MRP; Multidrug resistance; Polyglutamylation

Indexed keywords

DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROFOLIC ACID; FOLIC ACID; FOLINIC ACID; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; TRIMETREXATE;

ARTICLE; CELL GROWTH; CELL LEVEL; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; GENETIC TRANSFECTION; GROWTH STIMULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 0037333184     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01615-5     Document Type: Article

References (38)

1. Borst P., Elferink R.O. Mammalian abc transporters in health and disease. Annu. Rev. Biochem. 71:2002;537-592.
2. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
3. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science. 258:1992;1650-1654.
4. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., Miyake K., Resau J.H., Bates S. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113:2000;2011-2021.
5. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:2000;1295-1302.
6. Leslie E.M., Deeley R.G., Cole S.P.C. Toxicological relevance of the multidrug resistance protein 1 MRP1 (ABCC1) and related transporters. Toxicology. 167:2001;3-23.
7. Kool M., De Haas M., Scheffer G., Scheper R.J., Van Eijk M.J.T., Juin J.A., Baas F., Borst P. Analysis of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
8. Bertino J.R. Ode to methotrexate. J. Clin. Oncol. 11:1993;5-14.
9. Rots M.G., Pieters R., Kaspers G.J.L., Veerman A.J.P., Peters G.J., Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukemia. Br. J. Haematol. 109:2000;791-800.
10. Cronstein B.N. Methotrexate and its mechanism of action. Arthritis and Rheumatism. 39:1996;1951-1960.
11. Jackman AL. Antifolate drugs in cancer therapy. New Jersey, USA: Humana Press Inc.; 1999.
12. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., Scheper R.J., Borst P., Pinedo H.M., Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:1999;2532-2535.
13. Kool M., Van der Linden M., De Haas M., Scheffer G.L., De Vree M.L., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Oude Elferink R.P.V., Baas F., Borst P. MRP3, a new organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6914-6918.
14. Zeng H., Chen Z.S., Belinsky M.G., Rea P.A., Kruh G.D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of poly-glutamylation on MTX transport. Cancer Res. 61:2001;7225-7232.
15. Lee K., Klein-Szanto A.J., Kruh G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92:2000;1934-1940.
16. Chen Z.S., Lee K., Walther S., Blanchard Raftogianis R., Kuwano M., Zeng H., Kruh G.D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62:2002;3144-3150.
17. Sirotnak F.M., Wendel H.G., Bornmann W.G.B., Tong W.P., Miller V.A., Scher H.I., Kris M.G. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin. Cancer Res. 6:2000;3705-3712.
18. Henderson G.B., Zevely E.M. Inhibitory effect of probenecid on the individual transport routes which mediate the influx and efflux of methotrexate in L1210 cells. Biochem. Pharmacol. 34:1985;1725-1729.
19. Henderson G.B., Tsjui J.M., Kumar H.P. Characterization of the individual transport routes that mediate the influx and efflux of methotrexate in CCRF-CEM human lymphoblastic cells. Cancer Res. 46:1986;1633-1638.
20. Sirotnak F.M., O'Leary D.F. The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis and trans effects of inhibitors. Cancer Res. 51:1991;1412-1417.
21. Dembo M., Sirotnak F.M., Moccio D.M. Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: further evidence for separate influx and efflux systems with different energetic requirements. J. Membr. Biol. 78:1984;9-17.
22. Zhao R., Seither R., Brigle K.E., Sharina I.G., Wang P.J., Goldman I.D. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J. Biol. Chem. 272:1997;21207-21212.
23. Kusuhara H., Han Yhm Shimoda M., Kokue E., Suzuki H., Sugiyama Y. Reduced folate derivatives are endogenous substrates for cMOAT in rats. Am. J. Physiol. 275:1998;G789-G796.
24. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Schornagel J.H., Pinedo H.M., Peters G.J., Assaraf Y.G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 273:1998;30189-30198.
25. Zhao R., Gao F., Liu L., Goldman I.D. Marked suppression of the activity of some but not all antifolate compounds by augmentation of the folate cofactor pools within tumor cells. Biochem. Pharmacol. 61:2001;857-865.
26. Van der Wilt C.L., Backus H.H., Smid K., Comijn L., Veerman G., Wouters D., Voorn D.A., Priest D.G., Bunni M.A., Mitchell F., Jackman A.L., Jansen G., Peters G.J. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res. 61:2001;3675-3681.
27. Bunni M., Sirotnak F.M., Otter G.M., Priest D.G. Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium, and intraperitoneal L1210 cells of methotrexate-pretreated mice. Cancer Chemother. Pharmacol. 34:1994;455-458.
28. Scheffer G.L., Kool M., Heijn M., de Haas M., Pijnenborg A.C., Wijnholds J., van Helvoort A., de Jong M.C., Hooijberg J.H., Mol C.A., van der Linden M., de Vree J.M., van der Valk P., Elferink R.P., Borst P., Scheper R.J. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 60:2000;5269-5277.
29. Mauritz R., Peters G.J., Priest D.G., Assaraf Y.G., Drori S., Kathmann G.A., Noordhuis P., Bunni M.A., Rosowsky A., Schornagel J.H., Pinedo H.M., Jansen G. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem. Pharmacol. 63:2002;105-115.
30. Sirotnak F.M., Goutas L.J., Mines L.S. Extent of the requirement for folate transport by L1210 cells for growth and leukemogenesis in vivo. Cancer Res. 45:1985;4732-4734.
31. Chen L.Q.H., Korenberg J., Garrow T.A., Choi Y.J., Shane B. Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene. J. Biol. Chem. 271:1996;13077-13087.
32. Jansen G., Westerhof G.R., Jarmuszewski M.J.A., Kathmann I., Rijksen G., Schornagel J.H. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. J. Biol. Chem. 265:1990;18272-18277.
33. Jansen G., Barr H.M., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Peters G.J., Assaraf Y.G. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation expanded folate pools, and intralysosomal drug sequestration. Mol. Pharmacol. 55:1999;761-769.
34. Zingg J.M., Jones P.A. Genetic and epigenetic aspects of DNA methylation on genome expression evolution mutation and carcinogenesis. Carcinogenesis. 18:1997;869-882.
35. Jhaveri M.S., Wagner C., Trepel J.B. Impact of extracellular folate levels on global gene expression. Mol. Pharmacol. 60:2001;1288-1295.
36. Worm J., Kirkin A.F., Dzandzhugazyan K.N., Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J. Biol. Chem. 276:2001;39990-40000.
37. Backus H.H., Pinedo H.M., Wouters D., Padron J.M., Molders N., van Der Wilt C.L., van Groeningen C.J., Jansen G., Peters G.J. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int. J. Cancer. 87:2000;771-778.
38. Peters G.J., Jansen G. Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition. 17:2001;737-738.